Literature DB >> 8663598

Neuron-specific alternative splicing of nonmuscle myosin II heavy chain-B pre-mRNA requires a cis-acting intron sequence.

S Kawamoto1.   

Abstract

In addition to the ubiquitously expressed form of nonmuscle myosin II heavy chain-B (MHC-B), the existence of a neuron-specific MHC-B isoform, which contains a 30-nucleotide inserted sequence near the ATP binding region, has been reported (Takahashi, M., Kawamoto, S., and Adelstein, R. S.(1992) J. Biol. Chem. 267, 17864-17871). In this study, the genomic location of the neuron-specific inserted 30-nucleotide sequence found in the cDNA is determined to be a single cassette type exon, N30, in the human nonmuscle MHC-B gene. Inclusion or exclusion of exon N30 is cell type-specific, with inclusion being restricted to neuronal cells and being regulated during cell differentiation. Expression of a minigene construct that contains the alternative exon N30 along with the flanking introns and exons was studied in human neuronal retinoblastoma Y79 cells. Inclusion of the N30 exon in the mRNA from the transfected minigene occurs in differentiated Y79 cells that have been treated with butyrate but not in the undifferentiated Y79 cells and non-neuronal cell lines. Systematic deletion and mutation analysis of the minigene construct established that neuron-specific N30 exon recognition requires a cis-acting RNA sequence located approximately 1.5 kilobases downstream of the N30 exon.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663598

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Requirements for mini-exon inclusion in potato invertase mRNAs provides evidence for exon-scanning interactions in plants.

Authors:  C G Simpson; P E Hedley; J A Watters; G P Clark; C McQuade; G C Machray; J W Brown
Journal:  RNA       Date:  2000-03       Impact factor: 4.942

2.  Computational analysis of candidate intron regulatory elements for tissue-specific alternative pre-mRNA splicing.

Authors:  M Brudno; M S Gelfand; S Spengler; M Zorn; I Dubchak; J G Conboy
Journal:  Nucleic Acids Res       Date:  2001-06-01       Impact factor: 16.971

3.  Combinatorial control of a neuron-specific exon.

Authors:  E F Modafferi; D L Black
Journal:  RNA       Date:  1999-05       Impact factor: 4.942

4.  RBFOX2 promotes protein 4.1R exon 16 selection via U1 snRNP recruitment.

Authors:  Shu-Ching Huang; Alexander C Ou; Jennie Park; Faye Yu; Brian Yu; Angela Lee; Guang Yang; Anyu Zhou; Edward J Benz
Journal:  Mol Cell Biol       Date:  2011-11-14       Impact factor: 4.272

5.  Deciphering the splicing code.

Authors:  Yoseph Barash; John A Calarco; Weijun Gao; Qun Pan; Xinchen Wang; Ofer Shai; Benjamin J Blencowe; Brendan J Frey
Journal:  Nature       Date:  2010-05-06       Impact factor: 49.962

Review 6.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

7.  A complex intronic splicing enhancer from the c-src pre-mRNA activates inclusion of a heterologous exon.

Authors:  E F Modafferi; D L Black
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

8.  Molecular basis of RNA recognition by the human alternative splicing factor Fox-1.

Authors:  Sigrid D Auweter; Rudi Fasan; Luc Reymond; Jason G Underwood; Douglas L Black; Stefan Pitsch; Frédéric H-T Allain
Journal:  EMBO J       Date:  2005-12-15       Impact factor: 11.598

9.  Role for Fox-1/Fox-2 in mediating the neuronal pathway of calcitonin/calcitonin gene-related peptide alternative RNA processing.

Authors:  Hua-Lin Zhou; Andrew P Baraniak; Hua Lou
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

10.  A vertebrate RNA-binding protein Fox-1 regulates tissue-specific splicing via the pentanucleotide GCAUG.

Authors:  Yui Jin; Hitoshi Suzuki; Shingo Maegawa; Hitoshi Endo; Sumio Sugano; Katsuyuki Hashimoto; Kunio Yasuda; Kunio Inoue
Journal:  EMBO J       Date:  2003-02-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.